🇺🇸 Succinylcholine Chloride in United States

FDA authorised Succinylcholine Chloride on 20 August 1952

Marketing authorisations

FDA — authorised 20 August 1952

  • Marketing authorisation holder: SANDOZ
  • Status: approved

FDA — authorised 1 May 1953

  • Application: NDA008845
  • Marketing authorisation holder: HOSPIRA
  • Local brand name: QUELICIN PRESERVATIVE FREE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 20 September 1972

  • Application: ANDA080997
  • Marketing authorisation holder: ORGANON USA INC
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 4 May 2018

  • Application: ANDA209467
  • Marketing authorisation holder: ZYDUS PHARMS
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 16 November 2018

  • Application: ANDA211432
  • Marketing authorisation holder: AMNEAL
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 2 August 2019

  • Application: ANDA210698
  • Marketing authorisation holder: DR REDDYS
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 9 October 2019

  • Application: ANDA212638
  • Marketing authorisation holder: BRECKENRIDGE
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 15 January 2020

  • Application: ANDA211589
  • Marketing authorisation holder: SOMERSET THERAPS LLC
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 20 May 2020

  • Application: ANDA213705
  • Marketing authorisation holder: ACCORD HLTHCARE
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 22 May 2020

  • Application: ANDA214308
  • Marketing authorisation holder: REGCON HOLDINGS
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 12 June 2020

  • Application: ANDA213229
  • Marketing authorisation holder: HIKMA
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 16 June 2020

  • Application: ANDA214246
  • Marketing authorisation holder: GLAND
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 27 October 2020

  • Application: ANDA213552
  • Marketing authorisation holder: NEXUS
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 20 November 2020

  • Application: ANDA211346
  • Marketing authorisation holder: FRESENIUS KABI USA
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 24 November 2020

  • Application: ANDA214879
  • Marketing authorisation holder: MICRO LABS
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 21 December 2020

  • Application: ANDA214491
  • Marketing authorisation holder: DEVA HOLDING AS
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 29 March 2021

  • Application: ANDA215022
  • Marketing authorisation holder: SAGENT PHARMS INC
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 20 August 2021

  • Application: NDA215143
  • Marketing authorisation holder: HIKMA
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: SOLUTION — INTRAMUSCULAR, INTRAVENOUS
  • Status: approved

Read official source →

FDA — authorised 19 October 2021

  • Application: ANDA214514
  • Marketing authorisation holder: MEITHEAL
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 7 February 2022

  • Application: ANDA216003
  • Marketing authorisation holder: BE PHARMS
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 2 February 2023

  • Application: ANDA216127
  • Marketing authorisation holder: MANKIND PHARMA
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 16 October 2023

  • Application: ANDA217808
  • Marketing authorisation holder: EUGIA PHARMA
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 17 January 2024

  • Application: ANDA218467
  • Marketing authorisation holder: DR REDDYS
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: SOLUTION — INTRAMUSCULAR, INTRAVENOUS
  • Status: approved

Read official source →

FDA — authorised 9 July 2024

  • Application: ANDA217873
  • Marketing authorisation holder: STERISCIENCE
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: SOLUTION — INTRAMUSCULAR, INTRAVENOUS
  • Status: approved

Read official source →

FDA — authorised 24 September 2024

  • Application: ANDA218878
  • Marketing authorisation holder: BAXTER HLTHCARE CORP
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 11 February 2025

  • Application: ANDA217884
  • Marketing authorisation holder: FRESENIUS KABI USA
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: SOLUTION — INTRAMUSCULAR, INTRAVENOUS
  • Status: approved

Read official source →

FDA — authorised 21 February 2025

  • Application: ANDA217885
  • Marketing authorisation holder: FRESENIUS KABI USA
  • Local brand name: SUCCINYLCHOLINE CHLORIDE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

Succinylcholine Chloride in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in United States

Frequently asked questions

Is Succinylcholine Chloride approved in United States?

Yes. FDA authorised it on 20 August 1952; FDA authorised it on 1 May 1953; FDA authorised it on 20 September 1972.

Who is the marketing authorisation holder for Succinylcholine Chloride in United States?

SANDOZ holds the US marketing authorisation.